

## search result

ST-Pharm GmbH	Accounting/	Annual financial statements for the financial year	08/05/2021
<b>Surname</b>	<b>Area</b>	<b>information</b>	<b>V. date</b>

**ST-Pharm GmbH**

waders

**Annual financial statements for the financial year from January 1st, 2020 to December 31st, 2020****balance sheet****assets**

	12/31/2020 EUR	12/31/2019 EUR
A. Fixed assets	221,753.42	235,324.42
I. Tangible assets	221,753.42	235,324.42
B. Current Assets	1,047,818.39	1,316,552.33
I. Inventories	137,274.16	112,027.87
II. Receivables and other assets	369,546.79	475,540.35
III. Cash on hand, Bundesbank balances, bank balances and checks	540,997.44	728,984.11
C. Prepaid expenses	631.53	986.78
Total assets, total assets	1,270,203.34	1,552,863.53

**liabilities**

	12/31/2020 EUR	12/31/2019 EUR
A. Equity	57,447.14	76,257.19
I. Drawn capital	25,000.00	25,000.00
II. Balance sheet profit	32,447.14	51,257.19
B. Provisions	17,562.75	11,219.20
C. Liabilities	1,195,193.45	1,465,387.14
Balance sheet total, total liabilities	1,270,203.34	1,552,863.53

**Appendix****General information on the annual financial statements****Information on the identification of the company according to the register**

court Company name according to the register court: ST-Pharm GmbH

Company headquarters according to the register court: Wadern-Nunkirchen

Register entry: Commercial

register Register court: Saarbrücken

Register no.: B 16413

**Information on accounting and valuation methods Accounting and valuation****principles**

Das Property, plant and equipment were stated at acquisition or production cost and, where depreciable, reduced by scheduled depreciation.

Scheduled depreciation was carried out on a straight-line basis according to the expected useful life of the assets.

Inventories were recognized at acquisition or production cost. If the daily values on the balance sheet date were lower, they were used.

Receivables and other assets were valued taking into account all identifiable risks. Due to the general credit risk, a general allowance of 1% was made on the receivables that were not individually adjusted.

The tax provisions contain the taxes relating to the financial year that have not yet been assessed.

The other provisions were formed for all other contingent liabilities. All recognizable risks were taken into account.

Provisions and liabilities were recognized at the settlement amount.

#### **Accounting and valuation methods that differ from the previous year**

In the annual financial statements, the previously applied accounting and valuation methods were largely adopted.

There was no fundamental change in accounting and valuation methods compared to the previous year.

#### **Information on the balance sheet**

##### **Information on loans, receivables and liabilities to shareholders (§ 42 Para. 3 GmbHG / § 264c Para. 1 HGB)**

The following rights and obligations exist towards the shareholders:

<b>facts</b>	<b>2020</b>	<b>2019</b>
	<b>Euro</b>	<b>Euro</b>
loans	0.00	0.00
requirements	0.00	0.00
liabilities	110,920.78	331,040.12

#### **Profit/loss carryforward with partial**

appropriation of earnings When preparing the balance sheet taking into account the partial appropriation of earnings, a profit carryforward of EUR 51,257.19 was included in the retained earnings.

#### **Liabilities and security**

rights The total amount of recognized liabilities secured by liens or similar rights is EUR 33,848.96.

#### **Disclosure of notes on remaining terms All**

receivables have a remaining term of up to one year.

The amount of liabilities with a remaining term of up to one year is EUR 1,084,586.36 (previous year: EUR 1,310,757.53).

The amount of liabilities with a remaining term of more than one year is EUR 110,607.09 (previous year: EUR 154,629.61).

The total amount of recognized liabilities with a remaining term of more than 5 years is EUR 53,255.39 (previous year: EUR 67,767.93).

#### **Other information**

##### **Average number of employees during the financial year**

The average number of employees in the company during the financial year was 1.

##### **Advances and loans granted to directors**

Regarding the loans granted in favor of individual directors, the following is reported:

<b>credit development</b>	<b>amount</b>
	<b>Euro</b>
Status of previous loans	39,493.74
Repayments in the reporting year	0.00
New awards in the year under review	0.00
= new loan portfolio	39,493.74

#### **Signature of the management**

Wadern-Nunkirchen, April 30, 2021

\_\_\_\_\_  
Marc Moeckel

**other report components**

Information on the determination:

The annual financial statements were determined on June 7th, 2021.

---